Comparative Pharmacology
Head-to-head clinical analysis: PEMETREXED DISODIUM versus PEMETREXED DITROMETHAMINE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: PEMETREXED DISODIUM versus PEMETREXED DITROMETHAMINE.
PEMETREXED DISODIUM vs PEMETREXED DITROMETHAMINE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Pemetrexed is a folate analog metabolic inhibitor that disrupts folate-dependent metabolic processes essential for cell replication. It inhibits thymidylate synthase (TS), dihydrofolate reductase (DHFR), and glycinamide ribonucleotide formyltransferase (GARFT), thereby inhibiting de novo synthesis of thymidine and purine nucleotides.
Pemetrexed inhibits thymidylate synthase (TS), dihydrofolate reductase (DHFR), and glycinamide ribonucleotide formyltransferase (GARFT), enzymes involved in folate-dependent purine and pyrimidine synthesis, leading to disruption of DNA synthesis and cell death.
500 mg/m2 intravenously over 10 minutes on Day 1 of each 21-day cycle, with vitamin B12 and folic acid supplementation.
500 mg/m2 intravenously over 10 minutes every 21 days.
None Documented
None Documented
Terminal half-life is 3.5 hours in patients with normal renal function. Increases in renal impairment (up to 20 hours if CrCl <45 mL/min).
Terminal half-life 3.5 hours (range 2.5-5.0 hours) in patients with normal renal function; prolonged to 5-10 hours in moderate renal impairment. Clinical context: Half-life is dose-independent; clearance correlates with creatinine clearance.
Primarily renal excretion (70-90% as unchanged drug within 24 hours). Biliary/fecal excretion accounts for <5%.
Primarily renal excretion: 70-90% of the dose is eliminated unchanged in urine within 24 hours. Fecal excretion accounts for <5%.
Category C
Category C
Antineoplastic Antifolate
Antineoplastic Antifolate